norethindrone / Generic mfg. - LARVOL DELTA

Effectiveness of Medical Management in Heavy Menstrual Bleeding: A Prospective Cohort Study. (PubMed, Cureus) - "Medical management of HMB was effective in reducing menstrual blood loss and improving hemoglobin levels. LNG-IUS offered the most significant benefit with high compliance, but treatment choice should be individualized based on patient needs and clinical profile."

Journal • Women's Health

Results of relugolix/estradiol/norethisterone acetate combination therapy in real-world clinical practice: Effectiveness, tolerability, and factors influencing discontinuation. (PubMed, Eur J Obstet Gynecol Reprod Biol X) - "Discontinuation was most commonly due to planned surgery or perceived lack of efficacy. Relugolix CT demonstrates strong real-world effectiveness and tolerability for managing symptomatic uterine fibroids, with marked improvements in bleeding and quality of life, and a favourable safety profile."

Journal • Real-world evidence • Gynecology • Osteoporosis • Pain • Rheumatology • Solid Tumor • Uterine Leiomyoma • Women's Health

Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy. (PubMed, J Endocr Soc) - "Nonetheless, patient selection is essential, particularly for those with thrombotic risk factors. Continued real-world surveillance is crucial to refining its safety profile in clinical practice."

Journal • Review • Cardiovascular • Endometriosis • Gynecology • Solid Tumor • Uterine Leiomyoma • Venous Thromboembolism • Women's Health

Ormeloxifene Versus Norethisterone for Anovulatory Abnormal Uterine Bleeding: An India-Based Systematic Review and Meta-Analysis. (PubMed, Cureus) - "This meta-analysis suggests that ormeloxifene is more effective than norethisterone in improving clinical outcomes of AUB-O, with better control of menstrual blood loss, hemoglobin levels, and endometrial thickness. Larger, high-quality multicenter trials with longer follow-up are warranted to confirm long-term safety and efficacy."

Journal • Retrospective data • Review • Women's Health

Progestins as emerging contaminants in soil: An investigation on their pollution characteristics and ecological risks. (PubMed, Environ Res) - "The profiles of progestagenic activity exhibited differences with the concentration profiles, and three synthetic PGs (gestodene [GES], progesterone [P], and 19-norethindrone [NET]) were found to make significant contributions (36%-100%) to the progestagenic activity. A screening-level risk assessment based on limited data showed that terrestrial organisms might be under moderate or high risks posed by PGs in soil. The results can reveal the pollution profiles of PGs and provide basic data for the optimization of fertilization method to control PGs pollution in farmland system."

Journal

The effects of starter feed on intestinal fungi and non-targeted metabolomics of blood in calf yaks. (PubMed, BMC Microbiol) - "This feeding regimen was found to increase the concentrations of metabolites such as dexamethasone, benzamidine, norethindrone acetate, and tamoxifen, while simultaneously reducing the levels of metabolites like dinoterb and monoisobutyl phthalate. In conclusion, early supplementary feeding of starter feed is conducive to the colonization of beneficial fungi in the intestinal tract of calves, reduces the colonization of harmful bacteria, and increases the concentration of metabolites related to anti-inflammation, anti-tumor activity, and signal transduction in the blood of calves. Moreover, a feed formula consisting of 1.4 kg of alfalfa and 1.4 kg of starter feed proves advantageous for maintaining intestinal homeostasis and optimizing blood metabolism in calves, which could improve the overall productivity and health of yak calves.starter feedstarter feed."

Journal • Metabolic Disorders • Oncology

Sexual function in perimenopausal women treated with relugolix and add back therapy for uterine fibroids: an observational study. (PubMed, Eur J Contracept Reprod Health Care) - "The study included 21 premenopausal women affected by uterine fibroids with moderate-to-severe symptoms, treated with oral combination of relugolix 40 mg with ABT (oestradiol hemihydrate 1 mg + norethisterone acetate 0.5 mg). At 6 months no statistically significant changes in total FSFI scores were detected (23.0 +/- 8.0 vs 23.1 +/- 7.1, p 0.70); treatment resulted in a significant reduction in total volume (p 0.019) and mean diameter of fibroids (p 0.011) and in 87.5% of cases bleeding was effectively controlled. Treatment with relugolix-ABT was not associated with statistically significant changes in sexual function, with a good tolerability profile, while effectively reducing the fibroid size and controlling bleeding in most cases."

Journal • Observational data • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain. (PubMed, AJOG Glob Rep) - "The addition of hormonal add-back (AB) therapy (1-mg estradiol/0.5-mg norethindrone acetate once daily) may attenuate BMD loss. BMD remained mostly stable through 48 months of continuous treatment. This analysis represents the longest safety study of ELA+AB therapy to date and supports long-term treatment with ELA+AB therapy."

Journal • Endometriosis • Gynecology • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Otorhinolaryngology • Pain • Respiratory Diseases • Sinusitis • Women's Health

Adenomyosis with abnormal uterine bleeding complicated by venous thrombosis: a case series and literature review. (PubMed, Ann Med Surg (Lond)) - "Case 3 was a 49-year-old female who developed portal vein, splenic vein, and superior mesenteric vein thrombosis after long-term norethisterone therapy. Clinical experience indicates that GnRH-a combined with dienogest (DNG) can effectively control symptoms and preserve the uterus, but thrombotic risks require vigilance...When VTE occurs, total hysterectomy is often selected as the treatment. We attempted a combined regimen of GnRH-a, DNG, and anticoagulant therapy, which was effective in one case."

Journal • Cardiovascular • Endometriosis • Gynecology • Hematological Disorders • Thrombosis • Venous Thromboembolism • Women's Health

Injectable contraceptives differentially affect the hypothalamic-pituitary-gonadal axis and amenorrhea incidence†. (PubMed, Biol Reprod) - "The Women's Health Injectable Contraception and HIV trial randomised 521 women to intramuscular depot medroxyprogesterone acetate (DMPA-IM) or norethisterone enanthate (NET-EN) and showed similar decreased estradiol levels, but more amenorrhea for DMPA-IM users. HPO hormone profiles differ between DMPA-IM and NET-EN users and compared to pre- and post-menopausal women. Mechanisms affecting amenorrhea likely differ between contraceptives, with lower 25W LH/FSH being consistent with more amenorrhea for DMPA-IM."

Journal • Human Immunodeficiency Virus • Infectious Disease • Long-acting Reversible Contraceptives • Women's Health

Efficacy of low-dose mifepristone in patients with thrombotic disorders complicated by heavy menstrual bleeding (PubMed, Zhonghua Fu Chan Ke Za Zhi) - " (1) Among the 13 patients, venous thrombosis occurred in 8 cases (8/13), arterial thrombosis in 3 cases (3/13), and other types of thrombosis in 2 cases (2/13), including 1 case of local thrombosis after stent placement for anastomotic stenosis after renal transplantation, requiring long-term aspirin and clopidogrel, and 1 case of arteriovenous fistula thrombosis in a renal failure patient with long-term dialysis...(3) Management of acute bleeding stage: 6 patients with massive vaginal bleeding in emergency department were treated with dose reduction or withdrawal of antithrombotic drugs, 5 cases were treated with intrauterine Foley balloon compression hemostasis combined with mifepristone, 1 case was treated with oral norethindrone combined with mifepristone, and the bleeding was successfully stopped, and the antithrombotic therapy was resumed after 1-2 days...It effectively induces amenorrhea, enabling patients to safely navigate high-risk periods for both thrombosis..."

Journal • Retrospective data • Cardiovascular • Gynecology • Hematological Disorders • Nephrology • Renal Disease • Thrombosis • Transplantation • Women's Health

Ovulation Incidence in Oral Contraceptive Users (clinicaltrials.gov) - P3 | N=58 | Completed | Sponsor: University of Southern California | Suspended ➔ Completed

Trial completion

Non-additive effects of norethisterone and levonorgestrel mixtures on lipid metabolism at environmentally relevant concentrations. (PubMed, Aquat Toxicol) - "Notably, combined exposure suppressed both lipid synthesis and degradation pathways more strongly than individual treatments, leading to lipid accumulation and altered energy regulation. This study advanced understanding of the ecological risks caused by progestins in aquatic environments and highlighted the necessity of mixture-based risk assessment of endocrine-disrupting compounds."

Journal • Metabolic Disorders • FASN • PPARA • PPARG

A Randomized Feasibility Trial Comparing Drospirenone and Norethindrone for Postpartum Hypertension Management in Preeclampsia (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: Oregon Health and Science University

New P4 trial • Cardiovascular • Gynecology • Hypertension

HMB-BD: Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Oregon Health and Science University | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hemophilia

Comparative Efficacy of Ormeloxifene Versus Norethisterone Acetate in the Management of Abnormal Uterine Bleeding: A Randomized Controlled Trial. (PubMed, Cureus) - "Side effects were infrequent and well-controlled, and surgical intervention was rarely required. Conclusions Ormeloxifene demonstrates superior efficacy in reducing menstrual blood loss, improving anemia, and suppressing endometrial proliferation in women with AUB compared to norethisterone acetate, with an acceptable safety profile."

Journal • Gynecology • Hematological Disorders • Women's Health

Relugolix Combination Tablets in Healthy Japanese Premenopausal Women: Pharmacokinetics, Pharmacodynamics, and Safety Profile. (PubMed, Reprod Med Biol) - "To evaluate the applicability of overseas-approved dosage of relugolix combination tablets (relugolix 40 mg, estradiol [E2] 1 mg, and norethisterone acetate 0.5 mg) in healthy premenopausal Japanese women. Relugolix combination tablets have favorable safety and efficacy profiles, potentially making them suitable for long-term use in Japanese patients. The trial registration number is JapicRCT2071230042."

Clinical • Journal • PK/PD data

Management of uterine leiomyoma and adenomyosis: role of hysteroscopy in diagnosis and norethindrone in the treatment. (PubMed, Sci Rep) - "Hysteroscopy has effective role in differentiating between adenomyosis and fibroids. Yet, long term follows up of abnormal uterine bleeding cases with large sample size in future research are still warranted."

Journal • Endometriosis • Gynecology • Infectious Disease • Pain • Solid Tumor • Uterine Cancer • Uterine Leiomyoma • Women's Health

The origins of oral contraception: The role of Mexican scientists in developing the first synthetic oral contraceptive progestin. (PubMed, Rev Invest Clin) - "In fact, norethindrone and its derivatives from Syntex were soon available worldwide, becoming the most widely used progestins in oral contraceptives. This review examines the interactions between scientific and social history, clarifying the roles of key figures and situating Mexico's contributions within a broader global context of reproductive autonomy."

Journal

Bone mineral density with elagolix plus add-back therapy in women with heavy menstrual bleeding and uterine fibroids: open-label and post-treatment results of a 60-month phase 3 trial. (PubMed, AJOG Glob Rep) - P3 | "Premenopausal women aged 18-50 years with HMB associated with uterine fibroids were randomized 2:1 to receive ELA+AB therapy (ELA 300 mg twice daily plus estradiol 1.0 mg/norethindrone acetate 0.5 mg once daily) or placebo during double-blind treatment. The long-term use of ELA+AB therapy was well tolerated, with no new safety signals identified. These findings support the potential of long-term ELA+AB therapy for HMB associated with uterine fibroids."

Clinical • Journal • P3 data • Gynecology • Infectious Disease • Musculoskeletal Diseases • Novel Coronavirus Disease • Orthopedics • Solid Tumor • Uterine Leiomyoma • Women's Health

Trends in the use of oral contraceptives and progestins in Japanese female Olympic athletes. (PubMed, Phys Sportsmed) - "A significant shift occurred from OCs containing ≥30 µg of ethinylestradiol (EE) to those containing 20 µg of EE, and from desogestrel-based OCs to those containing drospirenone and norethisterone. This trend highlights the growing importance of gynecological support in elite sports. Future research should focus on the potential performance and health effects of the newer-generation formulations that are now predominantly used."

Journal

Venous thromboembolism in obese hormonal contraceptive users: a large national database study. (PubMed, Res Pract Thromb Haemost) - "Obese users of levonorgestrel + ethinyl estradiol (EE) had a VTE rate of 0.55% vs 0.33% in nonobese users (P = .01, relative risk [RR] = 1.63)...No significant differences were found for progesterone-only HT users. In this large study comparing rates of VTE among obese and nonobese females on HT, a significantly higher risk of VTE was observed among obese females using certain HTs, particularly EE with levonorgestrel, norethindrone, and norgestimate. These results highlight the importance of considering obesity as a key risk factor when prescribing HT, particularly for females with higher body mass index."

Journal • Cardiovascular • Genetic Disorders • Obesity • Venous Thromboembolism

Gestational Gigantomastia: A Century of Evidence with a New Case. (PubMed, Plast Reconstr Surg Glob Open) - "First-line medical therapy (bromocriptine, cabergoline, or norethindrone) achieved partial arrest in approximately 35% of trials; definitive control required surgery in 57% (reduction mammaplasty 29%, mastectomy 28%). Early recognition, prompt endocrine modulation, and timely, staged surgery are critical. We provide the largest curated dataset to date, quantify the mortality risk, and propose a stepwise management algorithm to guide multidisciplinary teams confronting this formidable obstetric challenge."

Journal • Hematological Disorders • Infectious Disease • Obstetrics • Septic Shock

Risk of Venous Thromboembolic Events Among Obese Hormonal Contraceptive Users (ASH 2023) - "VTE rates among obese users versus non-obese users was significantly higher for most progesterone only options (p<0.001), excluding drospirenone only pills and high dose norethindrone (Table 1)... Of the 97,026,002 females who met inclusion criteria, 1,370,481 were obese and 2,649,987 were non-obese. The overall rate of VTE for obese vs. non-obese users was 0.9% vs."

Cardiovascular • Genetic Disorders • Obesity • Venous Thromboembolism

Preoperative relugolix combination therapy in laparoscopic myomectomy: a case series evaluating impact on surgical planes and operative outcomes. (PubMed, Arch Gynecol Obstet) - "This case series suggests that preoperative Relugolix-CT does not adversely affect surgical planes or operative outcomes. Although preliminary, these findings suggest benefits for surgical optimisation and support further investigation in larger, controlled studies."

Journal • Fibrosis • Gynecology • Immunology • Solid Tumor • Uterine Leiomyoma • Women's Health